LRP5 and diabetic retinopathy: Similarly, F4L5.13, a tetravalent diabody with a dumbbell-like structure, has also been found to demonstrate comparable results in the treatment of diabetic retinopathy by acting against FZD4 and LRP5 receptors and LRP5 signaling [86].